The combination of the expression of hexokinase 2 and pyruvate kinase M2 is a prognostic marker in patients with pancreatic cancer

Ogawa,Hisataka; Nagano,Hiroaki; Konno,Masamitsu; Eguchi,Hidetoshi; Koseki,Jun; Kawamoto,Koichi; Nishida,Naohiro; Colvin,Hugh; Tomokuni,Akira; Tomimaru,Yoshito; Hama,Naoki; Wada,Hiroshi; Marubashi,Shigeru; Kobayashi,Shogo; Mori,Masaki; Doki,Yuichiro; Ishii,Hideshi

doi:10.3892/mco.2015.490

The combination of the expression of hexokinase 2 and pyruvate kinase M2 is a prognostic marker in patients with pancreatic cancer

Authors:
- Hisataka Ogawa
- Hiroaki Nagano
- Masamitsu Konno
- Hidetoshi Eguchi
- Jun Koseki
- Koichi Kawamoto
- Naohiro Nishida
- Hugh Colvin
- Akira Tomokuni
- Yoshito Tomimaru
- Naoki Hama
- Hiroshi Wada
- Shigeru Marubashi
- Shogo Kobayashi
- Masaki Mori
- Yuichiro Doki
- Hideshi Ishii
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565‑0871, Japan, Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Suita, Osaka 565‑0871, Japan, Department of Cancer Profiling Discovery, Osaka University Graduate School of Medicine, Suita, Osaka 565‑0871, Japan
Published online on: January 22, 2015 https://doi.org/10.3892/mco.2015.490
Pages: 563-571

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metabolism may determine the biologically malignant behavior of pancreatic cancer. To investigate the significance and prognostic value of cancer metabolism in cancer patients, we investigated the expression of two key enzymes in anaerobic glycolysis, hexokinase 2 (HK2) and pyruvate kinase isoenzyme type M2 (PKM2), in surgical specimens obtained from 36 patients who underwent curative resection of pancreatic ductal carcinoma. The HK2‑glycolysis axis is a key system in the clinical imaging of tumors via positron emission tomography. Immunohistochemical staining for HK2 and PKM2 was performed and the data were statistically analyzed to evaluate their prognostic power. The expression of HK2 and PKM2 was associated with clinicopathological variables and patient prognosis, including overall survival, local recurrence‑free survival and distant metastasis‑free survival. Staining for HK2 was negative and positive in 42 and 58% of the patients, respectively, whereas staining for PKM2 was negative and positive in 56 and 44%, respectively; HK2‑positive staining was correlated with progressive pathological tumor stage (pT3 vs. pT1 and pT2; P=0.017). In the univariate analysis, the positive expression of HK2 and PKM2, pathological stage (pT3 vs. pT1 and pT2) and nodal metastasis were significantly correlated with poor prognosis (P<0.03). In the multivariate analysis, pathological nodal metastasis was an independent prognostic factor for overall survival, whereas the positive expression of HK2 and PKM2 exhibited borderline significance (P=0.08 and 0.12, hazard ratio = 2.57 and 2.16, respectively). In addition, the combination of high expression of HK2 as well as PKM2 was found to be significant (P<0.05). These results suggested that the expression of HK2 and PKM2, particularly their combination, in surgical specimens obtained during curative resection, may predict an unfavorable clinical outcome in patients with pancreatic cancer.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics. 2012.CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
2	Feig C, Gopinathan A, Neesse A, Chan DS, Cook N and Tuveson DA: The pancreas cancer microenvironment. Clin Cancer Res. 18:4266–4276. 2012. View Article : Google Scholar : PubMed/NCBI
3	Amakye D, Jagani Z and Dorsch M: Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med. 19:1410–1422. 2013. View Article : Google Scholar : PubMed/NCBI
4	Özdemir BC, Pentcheva-Hoang T, Carstens JL, et al: Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 25:719–734. 2014. View Article : Google Scholar : PubMed/NCBI
5	Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD and Hingorani SR: Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 21:418–429. 2012. View Article : Google Scholar : PubMed/NCBI
6	Koong AC, Mehta VK, Le QT, et al: Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys. 48:919–922. 2000. View Article : Google Scholar : PubMed/NCBI
7	Campbell PJ, Yachida S, Mudie LJ, et al: The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 467:1109–1113. 2010. View Article : Google Scholar : PubMed/NCBI
8	Yachida S, Jones S, Bozic I, et al: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 467:1114–1117. 2010. View Article : Google Scholar : PubMed/NCBI
9	Yamada S, Fuchs BC, Fujii T, et al: Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer. Surgery. 154:946–954. 2013. View Article : Google Scholar : PubMed/NCBI
10	Chan N, Milosevic M and Bristow RG: Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncol. 3:329–341. 2007. View Article : Google Scholar : PubMed/NCBI
11	Kroemer G and Pouyssegur J: Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell. 13:472–482. 2008. View Article : Google Scholar : PubMed/NCBI
12	Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
13	Christofk HR, Vander Heiden MG, Harris MH, et al: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 452:230–233. 2008. View Article : Google Scholar : PubMed/NCBI
14	Wolf A, Agnihotri S, Micallef J, et al: Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med. 208:313–326. 2011. View Article : Google Scholar : PubMed/NCBI
15	Mitsunaga S, Hasebe T, Iwasaki M, Kinoshita T, Ochiai A and Shimizu N: Important prognostic histological parameters for patients with invasive ductal carcinoma of the pancreas. Cancer Sci. 96:858–865. 2005. View Article : Google Scholar : PubMed/NCBI
16	Mitsunaga S, Hasebe T, Kinoshita T, et al: Detail histologic analysis of nerve plexus invasion in invasive ductal carcinoma of the pancreas and its prognostic impact. Am J Surg Pathol. 31:1636–1644. 2007. View Article : Google Scholar : PubMed/NCBI
17	Takahashi H, Ohigashi H, Ishikawa O, et al: Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer. Ann Surg. 255:95–102. 2012. View Article : Google Scholar : PubMed/NCBI
18	Nakata B, Fukunaga S, Noda E, Amano R, Yamada N and Hirakawa K: Chemokine receptor CCR7 expression correlates with lymph node metastasis in pancreatic cancer. Oncology. 74:69–75. 2008. View Article : Google Scholar : PubMed/NCBI
19	Komoto M, Nakata B, Amano R, et al: HER2 overexpression correlates with survival after curative resection of pancreatic cancer. Cancer Sci. 100:1243–1247. 2009. View Article : Google Scholar : PubMed/NCBI
20	Javle MM, Gibbs JF, Iwata KK, et al: Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol. 14:3527–3533. 2007. View Article : Google Scholar : PubMed/NCBI
21	Guillaumond F, Iovanna JL and Vasseur S: Pancreatic tumor cell metabolism: focus on glycolysis and its connected metabolic pathways. Arch Biochem Biophys. 545:69–73. 2014. View Article : Google Scholar : PubMed/NCBI
22	Semenza GL: Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 29:625–634. 2010. View Article : Google Scholar : PubMed/NCBI
23	Semenza GL: HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev. 20:51–56. 2010. View Article : Google Scholar : PubMed/NCBI
24	Peitzsch C, Perrin R, Hill RP, Dubrovska A and Kurth I: Hypoxia as a biomarker for radioresistant cancer stem cells. Int J Radiat Biol. 90:636–652. 2014. View Article : Google Scholar : PubMed/NCBI
25	Medina RA and Owen GI: Glucose transporters: expression, regulation and cancer. Biol Res. 35:9–26. 2002. View Article : Google Scholar : PubMed/NCBI
26	Airley RE and Mobasheri A: Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy. 53:233–256. 2007. View Article : Google Scholar : PubMed/NCBI
27	Haber RS, Rathan A, Weiser KR, et al: GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 83:34–40. 1998. View Article : Google Scholar : PubMed/NCBI
28	Rempel A, Mathupala SP and Perdersen PL: Glucose catabolism in cancer cells: regulation of the Type II hexokinase promoter by glucose and cyclic AMP. FEBS Lett. 385:233–237. 1996. View Article : Google Scholar : PubMed/NCBI
29	Mathupala SP, Rempel A and Pedersen PL: Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr. 29:339–343. 1997. View Article : Google Scholar : PubMed/NCBI
30	Di Chiro G, DeLaPaz RL, Brooks RA, et al: Glucose utilization of cerebral gliomas measured by [¹⁸F] fluorodeoxyglucose and positron emission tomography. Neurology. 32:1323–1329. 1982. View Article : Google Scholar : PubMed/NCBI
31	Pedersen PL: Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the ‘Warburg Effect’, i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr. 39:211–222. 2007. View Article : Google Scholar : PubMed/NCBI
32	Mazurek S: Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours. Ernst Schering Found Symp Proc. 43:969–980. 2007.
33	Bardeesy N and DePinho RA: Pancreatic cancer biology and genetics. Nat Rev Cancer. 2:897–909. 2002. View Article : Google Scholar : PubMed/NCBI
34	Manning BD and Cantley LC: AKT/PKB signaling: navigating downstream. Cell. 129:1261–1274. 2007. View Article : Google Scholar : PubMed/NCBI
35	Ramanathan A, Wang C and Schreiber SL: Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci USA. 102:5992–5997. 2005. View Article : Google Scholar : PubMed/NCBI
36	Feron O: Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol. 92:329–333. 2009. View Article : Google Scholar : PubMed/NCBI
37	Lyshchik A, Higashi T, Hara T, et al: Expression of glucose transporter-1, hexokinase-II, proliferating cell nuclear antigen and survival of patients with pancreatic cancer. Cancer Invest. 25:154–162. 2007. View Article : Google Scholar : PubMed/NCBI
38	Mamede M, Higashi T, Kitaichi M, et al: [¹⁸F] FDG uptake and PCNA, Glut-1 and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia. 7:369–379. 2005. View Article : Google Scholar : PubMed/NCBI
39	Sato-Tadano A, Suzuki T, Amari M, et al: Hexokinase II in breast carcinoma: a potent prognostic factor associated with hypoxia-inducible factor-1α and Ki-67. Cancer Sci. 104:1380–1388. 2013. View Article : Google Scholar : PubMed/NCBI
40	Li J, Yang Z, Zou Q, et al: PKM2 and ACVR 1C are prognostic markers for poor prognosis of gallbladder cancer. Clin Transl Oncol. 16:200–207. 2014. View Article : Google Scholar : PubMed/NCBI
41	Lim JY, Yoon SO, Seol SY, et al: Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer. World J Gastroenterol. 18:4037–4043. 2012. View Article : Google Scholar : PubMed/NCBI
42	Luo W and Semenza GL: Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget. 2:551–556. 2011.PubMed/NCBI